16th Feb 2015 06:53
LONDON (Alliance News) - AstraZeneca PLC late on Friday said a US court has ruled its patent on its Pulmicort Repsules asthma treatment invalid, but said the decision will not impact its guidance for 2015.
The FTSE 100-listed pharmaceutical company said the US District Court for the District of New Jersey has ruled the patent protecting the product in the US is invalid.
?AstraZeneca strongly disagrees with the court?s decision,? said Paul Hudson, president of AstraZeneca US and executive vice president for the company in North America. ?AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Repsules. We are reviewing the decision and considering our legal options, including an appeal.?
The group said the decision does not impact on the validity of its patents for the product in other countries.
AstraZeneca said the decision will not impact its guidance for 2015.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca